Taking Aim at Cancer Costs
To promote the use of lower-cost generic chemotherapy drugs, Calabria says HAP has worked to increase—not decrease—the provider reimbursement for generic oncology drugs. Cutting reimbursements would be a "disincentive" for physicians to use generics, according to Calabria.
"This isn't a utilization management program," he explains. "We don't want to discourage generic usage by not reimbursing correctly."
Calabria acknowledges that oncology cost and treatment management is a "new frontier. It's emotional." Among the hoped-for outcomes of the program is that the pathways provide physicians and patients with the clinical support they need to feel more comfortable with getting ready for end-of-life care. "At some point we need to stop treatment when there's no support for it anymore."
Calabria expects the HAP program to get underway later this year.
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- Top Reason for Nurse Turnover: Managers
- CEO Exchange: Pressure is On to Partner, Drive Quality
- Interventional Radiology No Longer a Sub-Specialty
- Behind the CVS Health Rebranding Strategy
- CMS Pitches Medicare Appeals Deal to Hospitals
- Mobile Health Screenings Come Under Scrutiny
- How MA plans to re-enroll 450,000 residents in health insurance
- House OKs Cassidy's 'keep your plan' bill
- Medicare is pricier in unhealthy states, study says
- Washington, Wall Street Gauge HIX Performance as Open Enrollment Nears